{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT04565444: Not Applicable Interventional Completed Ketosis
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT04314856: Phase 1 Interventional Withdrawn Fragile X Syndrome (FXS)
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02647320: Phase 2 Interventional Completed Type 2 Diabetes Mellitus
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03912350: Phase 1 Interventional Withdrawn Autism Spectrum Disorder
(2022)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00815763: Phase 3 Interventional Completed Ischemic Stroke
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT01931943: Phase 1 Interventional Unknown status Advanced Breast Cancer
(2013)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Qilu Pharmaceutical has developed selatinib, an orally available dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 receptor (HER-2) for the treatment of cancer. Selatinib participates in phase I of the ongoing clinical trial to evaluate its safety and tolerability, and explore the maximum tolerated dose (MTD) and dose-limiting toxicity in patients with advanced breast cancer.
Status:
Investigational
Source:
NCT01520649: Phase 1 Interventional Completed Depression
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
NSI-189 is a novel oral drug which was developed by Neuralstem for the treatment of cognitive disorders. Now the drug is being tested in phase II of clinical trials in patients suffering from major depressive disorder. The mechanism of NSI-189 action is explained by its ability to stimulate the generation of new neurons in the hippocampus, however the exact target molecule is still unknown.
Status:
Investigational
Source:
NCT00376454: Phase 2 Interventional Completed Neuropathic Pain
(2002)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
GW-493838 was developed by GlaxoSmithKline as an adenosine A1A receptor agonist for the treatment of dyslipidemia and neuropathic pain. GW493838 participated in the phase II clinical trial to determine the analgesic effect in patients with post-herpetic neuralgia or peripheral nerve injury caused by trauma or surgery. However, this study has been discontinued.
Status:
Investigational
Source:
NCT02808390: Phase 2 Interventional Terminated Ulcerative Colitis
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
